VolitionRx Limited to Present at Conferences in March 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Nio stock jumps after Goldman Sachs upgrade to buy
- Wall Street posts weekly gains with earnings, inflation data on tap
Cantor Fitzgerald Starts VolitionRX (VNRX) at Overweight
March 9, 2021 4:08 PM ESTCantor Fitzgerald analyst Kyle Mikson initiates coverage on VolitionRX (NYSE: VNRX) with a Overweight rating and a price target of $8.00.
The analyst comments "We are initiating coverage of VolitionRx (VNRX) with an Overweight rating and a 12-month price target of $8. The company is developing a suite of blood-based (liquid... More



